Boehringer Ingelheim

Global medical leadership and successful worldwide market launch of PRADAXA in three main indications (prevention of venous thromboembolism [VTE] after orthopaedic surgery, stroke prevention in patients with atrial fibrillation, and treatment of VTE).
Conducting the global approval process for PRADAXA in the SPAF indication with achievement of blockbuster status within eleven months.
Building a global Brand Medical Affairs team with international structure and group leaders, growing the team from 2 to 8 people and subsequently managing a team of 12 people.
Head of a team managing the global launch of a blockbuster core brand with cross-functional collaboration in the global brand team structure including Marketing, Market Access, Epidemiology, Drug Regulatory Affairs, Drug Safety, and Communications.
Matrix structure management of specific launches in major EU countries with respective launch readiness management.
Team membership in the CV Strategy Team, active membership in the International Medical Committee, and permanent guest in the International Commercial Committee.
Initiating antidote development for PRADAXA as well as publishing several guidelines and scientific articles on clinical challenges such as bleeding emergencies, dialysis and intoxications.
Global responsibility as Medical Director for the core brand in the CV portfolio (Telmisartan), working on the development of 3 different Fixed Dose Combinations (FDCs).
Membership in the Development Team of the Diabetes portfolio with global strategy for in-market brands and Medical Affairs representation in multiple development programs.
Generation of the Phase III development program for the Fixed Dose Combination (Telmisartan/Amlodipine).
Developing a global clinical development plan for TWYNSTA.
Conceptualizing and implementing a worldwide KOL database.
Building a Real-World Evidence organization and implementing the GLORIA-AF registry.
Co-chairing the global pharmacovigilance working group.

Andreas Clemens × C.H. Boehringer Sohn AG & Co. KG — Employment Period

Achievements